Navigation Links
S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
Date:5/4/2010

r cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors.ONX 0801, a targeted alpha-folate inhibitor, is currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

Forward-Looking Statements

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws.  These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of SB1518 (ONX 0803) and SB1578 (ONX 0805).  These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.  Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 20
'/>"/>

SOURCE S*BIO Pte Ltd; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
2. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
3. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
4. S*BIO Completes US$26 Million Equity Financing
5. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
6. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
7. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
8. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
9. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
10. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
11. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Solutions, LLC, Santa Clara, CA, a manufacturer of ... applications, announced the release of TruTorr(TM), a single-use ... containers, in order to prevent overpressure damage, at ... TruTorr system consists of a disposable pressure sensor, ...
... option for millions of Americans with debilitating lung ... (NYSE: AZN ) today announced that ... approved SYMBICORT (budesonide/formoterol fumarate dihydrate) 160/4.5 mcg for ... in patients with chronic obstructive pulmonary disease (COPD), ...
... Is Just What Diabetics Have Been Waiting For. The Sleek, Bold ... By Storm. , ... Greenville, SC (PRWEB) February 27, 2009 -- For ... that is both functional and attractive. In recent years, many companies ...
Cached Biology Technology:Finesse Announces TruTorr(TM) Single-Use Pressure Sensor 2FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 2FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 3FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 4FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 5FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 6Home Delivery Medical Offers New Glucose Meter With State-Of-The-Art Technology 2Home Delivery Medical Offers New Glucose Meter With State-Of-The-Art Technology 3
(Date:4/23/2014)... Putnam Valley, NY. (Apr. 23 2014) ... human neural stem cells (hNSCs) into the brains ... differentiation after 22 and 24 months found that ... months and did not cause tumors. , The ... of Cell Transplantation but is currently ...
(Date:4/23/2014)... trope that the likelihood of an accurate group decision ... hold up when a collective faces a variety of ... Instead, Princeton University researchers report that smaller groups actually ... may become excessively focused on only certain pieces of ... what is known about collective intelligence, or the "wisdom ...
(Date:4/23/2014)... a signing ceremony in Buenos Aires yesterday, Argentina ... an associate member state. The move strengthens the ... science communities. It grants Argentinian scientists access to ... beneficial collaborations. , "Ever since its inception, fostering ... have been at the core of EMBL,s mission," ...
Breaking Biology News(10 mins):Study finds long-term survival of human neural stem cells transplanted into primate brain 2Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
... OTO EXPO of the American Academy of Otolaryngology Head ... nose, and throat doctors in the world, will convene September ... scientific research sessions, 594 posters, and several hundred instruction course ... for journalists from around the world to cover breaking science ...
... 2010 - Eurofins MWG Operon, an expert in next generation ... GS Junior. The GS Junior is the optimum system for ... one eighth of the capacity of a GS FLX Titanium ... run. As a consequence, the GS Junior adds a higher ...
... This release is available in French ... high electrical conductivity that promise to revolutionize a wide range ... A team of McGill University researchers have now reported ... along one single conductive polymer molecule at a time, a ...
Cached Biology News:2010 AAO-HNSF miniseminars: Tuesday, Sept. 28, 2010 22010 AAO-HNSF miniseminars: Tuesday, Sept. 28, 2010 3Striding towards a new dawn for electronics 2